Pinealon

Pinealon is a short peptide bioregulator - a tripeptide - originally studied in the context of brain aging and sleep regulation. It is one of a class of peptides developed through Russian bioregulator research that began in the 1970s and 1980s. How it works: Pinealon is thought to support neuronal gene expression and improve neuronal resilience. The mechanism is described as supporting brain bioregulation - the peptide may influence how neurons read and respond to their own genetic instructions. The clinical data behind this mechanism is limited. Who tends to use it: People focused on cognition and longevity, particularly in the context of brain aging. It also carries a minor rating for sleep, consistent with its pineal gland origin. Pinealon is often paired with Epitalon, another bioregulator from the same research tradition. How it is taken: Pinealon is given by subcutaneous (SC) injection. It is administered in short courses of 10-20 days, with daily dosing during each course, in the morning. Specific doses are set at consult - the record does not publish a general range, because the course-based structure is highly individualized. What to expect: This peptide has limited clinical data by modern standards. The evidence is classified as anecdotal, meaning it comes primarily from observational use rather than controlled trials. Effects, if present, are likely to be gradual and subtle across the course. Safety: The record notes limited clinical data as the primary caution. There are no excludeIf flags - no contraindications for pregnancy or cancer history are listed. Pinealon has no known significant adverse effects in the bioregulator literature, but thorough clinical evaluation before use is appropriate given how sparse the human data is. Your licensed provider in the PepDepo network will assess whether Pinealon fits your goals and determine the course protocol at consult.